Study of endothelial vascular growth factor, markers of inflammation and vascular stiffness in chronic kidney disease


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Purpose of the study. Assessment of the levels of vascular endothelial growth factor, markers of inflammation and their relationship with vascular stiffness indices in chronic kidney disease. Material and methods. 261 patient with chronic kidney disease (CKD) of stages 1-5 were examined, the average age was 51.з±15.8 years. depending on the cause of the development of ckd, the entire sample was divided into several groups: 1st - arterial hypertension (ah) - 59 (22.6%); 2nd - diabetes mellitus (DM) - 46 patients (17.6%); 3rd - coronary heart disease (CHD) - 48 (18.4%); 4th - chronic obstructive pulmonary disease (COPD) - 23 (8.8%); 5th - chronic glomerulonephritis (CGN) - 38 (14.6%); 6th - chronic tubulointerstitial nephritis (Chtin) - 47 (18.0%) and the 7th group - comorbid pathology - 97 (37.1%) cases. All participants underwent clinical, instrumental and laboratory studies. Vascular stiffness parameters, markers of inflammation, and the concentration of endothelial vascular growth factor (VEGF, pg/ml) were evaluated. glomerular filtration rate (GFR) was calculated using the formula ckd-epi (Chronic kidney disease epidemiology Collaboration). results. levels of central blood pressure were significantly higher in individuals with cp. the highest stiffness index and alternative stiffness index were characteristic for patients with cgn and copd. a significant increase in augmentation index and increase index at a pulse rate of 75 per minute was recorded in the groups of hypertension, type 2 diabetes and cp. higher levels of the vascular wall reflection index were observed in patients with hypertension and cp. median levels of total cholesterol (Ch), triglycerides and low density lipoproteins Ch (LDL Ch) in blood plasma were significantly higher in individuals with hypertension. the concentration of high density lipoprotein cholesterol was the lowest among patients with cgn. the proportion of patients with a high content of c-reactive protein (CRP) in blood plasma significantly prevailed in the groups of hypertension (81.3%) and coronary heart disease (79.1%). The median fibrinogen content was significantly higher in individuals with cp. The highest levels of phosphorus were observed among patients with type 2 diabetes and cgn, and calcium in the group of individuals with hypertension. blood plasma vegf concentration was significantly higher in the groups of cgn: 202.08 (91.42-356.48) pg/ml, chtiN: 208.85 (113.h-355.09) pg/ml and KP: 213,54 (95.04-372.71) pg/ml, which was accompanied by an increase in blood plasma creatinine. the calculated gfr was significantly lower in individuals with type 2 diabetes: 46.5 (33.2-62.6) ml/min and CP: 62.0 (27.o-78.0) ml/min. a direct correlation relationship between the vegf concentration and the value of the alternative vascular stiffness index (r=0.440; p<0.001) and fibrinogen (r=0.239; p<0.05) blood was established, and the feedback was correlated with the estimated gfr (r=-0.491; p<0.001). crp levels positively correlated with an alternative vascular stiffness index (r=0.434; P<0.001). Conclusions. a significant increase in the level of vascular endothelial growth factor was observed in patients with chronic tubulointerstitial nephritis and glomerulonephritis, as well as in individuals with comorbid pathology, which was accompanied by an increase in blood plasma creatinine. in chronic kidney disease, the level of endothelial vascular growth factor is a risk factor for a decrease in glomerular filtration rate and vascular stiffness. An increase in the content of C-reactive protein is associated with an increase in the rigidity of the vascular wall, and a concentration of endothelial vascular growth factor is associated with hyperfibrinogenemia.

Full Text

Restricted Access

About the authors

I. T Murkamilov

Kyrgyz State Medical Academy named after I.K. Akhunbaev; Kyrgyz Russian slavic university

Email: murkamilov.i@mail.ru
PhD in Medical Sciences, Nephrologist, Deputy Associate Professor at the Department of Faculty Therapy I.K. Akhunbaev KSMA, Kyrgyz-Russian Slavic University Bishkek, Kyrgyzstan

K. A Aitbaev

Scientific and research Institute of molecular biology and medicine

Email: kaitbaev@yahoo.com
Doctor of Medical Sciences, Professor, Head of the Laboratory of Pathological Physiology, Research Institute of Molecular Biology and Medicine Bishkek, Kyrgyzstan

V. V Fomin

FSAEI HE First Moscow State Medical University named after I.M. Sechenov

Email: fomin_vic@mail.ru
Doctor of Medical Sciences, Professor, Corresponding Member of the Russian Academy of Sciences, Vice-Rector for Clinical Work and Postgraduate Professional Education, Director of the V.N. Vinogradov Faculty Therapy Clinic, Head of the Faculty Therapy Department № 1, Sechenov First MSMU Moscow, Russia

Zh. A Murkamilova

Kyrgyz Russian slavic university

Email: murkamilovazh.t@mail.ru
correspondence post-graduate student of the Department of Therapy № 2 of the specialty "General Medicine" Kyrgyz-Russian Slavic University n.a. the First President of the Russian Federation B.N. Yeltsin Bishkek, Kyrgyzstan

F. A Yusupov

Osh State University

Email: furcat_y@mail.ru
Doctor of Medical Sciences, Professor, Head of the Department of Neurology and Psychiatry, Faculty of Medicine Osh, Kyrgyzstan

N. A Redzhapova

Osh State University

Email: nredzhapova@mail.ru:
Postgraduate Student at the Department of Neurology and Psychiatry, Faculty of Medicine Osh, Kyrgyzstan

Z. R Rayimzhanov

Kyrgyz State Medical Academy named after I.K. Akhunbaev

Email: rzrmam@mail.ru
correspondence graduate student of I.K. Akhunbaev KSMA Bishkek, Kyrgyzstan

A. I Schastlivenko

Vitebsk State Order of Peoples Friendship Medical University

Email: andrei.schastlivenko@mail.ru
PhD in Medical Sciences, associate professor of the department of general practitioner with a course of outpatient therapy Vitebsk, Russia

References

  1. Моисеев В.С., Мухин Н.А. Национальные рекомендации. Сердечнососудистый риск и хроническая болезнь почек: стратегии кардионе-фропротекции. Клиническая нефрология. 2014;2:4-29
  2. Li P.K., Garcia-Garcia G, Lui S.F., et al. Здоровые почки всем и везде: от профилактики и выявления до равного доступа к медицинской помощи. Клиническая нефрология. 2020;1:18-26. https://dx.doi.org/10.18565/ nephrology.2020.1.18-26
  3. Шилов Е.М., Котенко О.Н., Шилова М.М. и др. Состояние нефрологической службы: заместительная почечная терапия в Российской Федерации в период с 2015 по 2019 г. Клиническая нефрология. 2020;1:6-17
  4. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nature Med. 2003;9(6):669-76. https://doi.org/10.1038/nm0603-669
  5. Marino M., Del Bo C, Tucci M., et al. Modulation of Adhesion Process, E-Selectin and VEGF Production by Anthocyanins and Their Metabolites in an In-Vitro Model of Atheroscleros. 2020;12:655. https://doi.org/10.3390/ nu12030655
  6. Kikuchi R., Stevens M., Harada K., et al. Anti-angiogenic isoform of vascular endothelial growth factor-A in cardiovascular and renal disease. Advances in clinical chemistry. Elsevier. 2019;88:1-33. https://doi.org/10.1016/ bs.acc.2018.10.001
  7. Бобкова И.Н., Чеботарева Н.В., Козловская Л.В., Непринцева Н.В. Защитное действие белков теплового шока при заболеваниях почек. Клиническая нефрология. 2011;6:59-66.
  8. Lavin-Gomez B.A., Palomar-Fontanet R., Gago-Fraile M., et al. Inflammation markers, chronic kidney disease, and renal replacement therapy. Advances in peritoneal dialysis. Conference on Peritoneal Dialysis. 2011;27:33-7. PMID: 22073825.
  9. Оганов Р.Г., Денисов И.Н., Симаненков В.И. и др. Коморбидная патология в клинической практике. Клинические рекомендации. Кардиоваскулярная терапия и профилактика. 2017;16(6):5-56.
  10. Парфенов А.С. Экспресс-диагностика сердечно-сосудистых заболеваний. Мир измерений. 2008;6:74-82
  11. Levey A.S., De Jong P.E., Coresh J., et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80(1):17-28. https://doi.org/10.1038/ki.2010.483
  12. Widmer R.J., Lerman A. Endothelial dysfunction and cardiovascular disease. Global Cardiol. Sci. Pract. 2014;2014(3):43. https://doi.org/10.5339/ gcsp.2014.43
  13. Triantafyllou C., Nikolaou M., Ikonomidis I., et al. Endothelial and Cardiac Dysfunction in Inflammatory Bowel Diseases: Does Treatment Modify the Inflammatory Load on Arterial and Cardiac Structure and Function? Curr. Vasc. Pharmacol 2020;18(1):27-37. https://doi.org/10.2174/15701611176 66181129095941
  14. Шулькина С.Г., Смирнова Е.Н., Желобов В.Г. Клиническое значение маркеров эндотелиальной дисфункции в диагностике функционального состояния почек у больных с артериальной гипертензией в сочетании с ожирением. Журнал здоровье и образование в XXIвеке. 2016;5(18):19-24.
  15. Zhang J., Chu M. Differential roles of VEGF: Relevance to tissue fibrosis. J. Cell. Biochem. 2019;120(7):10945-51. https://doi.org/10.1002/jcb.28489
  16. Gnudi L., Benedetti S., Woolf A.S., Long D.A. Vascular growth factors play critical roles in kidney glomeruli. Clin. Sci. (Lond). 2015;129(12):1225-36. https://doi.org/10.1042/CS20150403
  17. Kim N.H., Kim K.B., Kim D.L., et al. Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in Type 2 diabetes mellitus. Diabet. Med. 2004;21(6):545-51. https://doi.org/10.1111/j.1464-5491.2004.01200.x
  18. Iglesias-de la Cruz M.C., Ziyadeh F. N., Isono M., et al. Effects of high glucose and TGF-/31 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. Kidney Int. 2002;62(3):901-13. https://doi. org/10.1046/j.1523-1755.2002.00528.x
  19. Kim N. H., Oh J. H., Seo J. A., et al. Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. Kidney Int. 2005;67(1):167-77. https://doi.org/10.1111/j.1523-1755.2005.00067.x
  20. Schrijvers B.F., Fyvbjerg A., De Vriese A.S. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int. 2004;65(6):2003-17. https://doi.org/10.1111/j.1523-1755.2004.00621.x
  21. Pawlak K., Ulazka B., Mysliwiec M., Pawlak D. Vascular endothelial growth factor and uPA/suPAR system in early and advanced chronic kidney disease patients: a new link between angiogenesis and hyperfibrinolysis? Translational Res. 2012;160(5):346-54. https://doi.org/10.1016/j.trsl.2012.04.004
  22. Климонтов В.В., Еременко Н.В., Мякина Н.Е., Фазуллина О.Н. Цистатин С и коллаген IV типа в диагностике хронической болезни почек у больных сахарным диабетом 2го типа. Сахарный диабет. 2015;1:87-93.
  23. Zanoli L., Lentini P., Briet M., et al. Arterial stiffness in the heart disease of CKD. Journal of the Am. Soc Nephrol. 2019;30(6):918-28. https://doi. org/10.1681/ASN.2019020117
  24. Eimery S., Tangestani H., Mansouri S., et al. Association between dietary patterns with kidney function and serum highly sensitive C-reactive protein in Tehranian elderly: An observational study. J. Res. Med. Sci.: Off. J. Isfahan Univer. Med. Sci. 2020;25:19. https://dx.doi.org/10.4103/jrms.JRMS_812_18
  25. Ghazizadeh H., Rezaei M., Avan A., et al. Association between serum cell adhesion molecules with hs-CRP, uric acid and VEGF genetic polymorphisms in subjects with metabolic syndrome. Mol. Boil. Reports. 2020;47(2):867-75. https://doi.org/10.1007/s11033-019-05081-2
  26. Денисенко М.Н., Генкель В.В., Салашенко А.О. и др. Жесткость артерий мышечного и эластического типов у больных с атеросклерозом периферических артерий. Кардиоваскулярная терапия и профилактика. 2016;15(5):70-3.
  27. Yasmin McEniery C.M., Wallace S., Mackenzie I. S., et al. C-reactiveprotein is associated with arterial stiffness in apparently healthy individuals. Arterioscler. Thromb. Vasc. Biol. 2004;24(5):969-74. https://doi.org/10.1161/01.ATV. zhq0504.0173
  28. Заирова А.Р, Рогоза А.Н., Добровольский А.Б. и др. Артериальная жесткость и «сосудистое старение» во взаимосвязи с коагулогическими факторами риска развития сердечно-сосудистых заболеваний, показателями липидного и углеводного обмена в популяции взрослого населения Томска по данным исследования ЭССЕ-РФ. Кардиологический вестник. 2018;13(1):5-15.
  29. Yang S.H., Du Y., Zhang Y., et al. Serum fibrinogen and cardiovascular events in Chinese patients with type 2 diabetes and stable coronary artery disease: a prospective observational study. BMJ. Open. 2017;7(6):e015041. http://dx.doi. org/10.1136/bmjopen-2016-015041
  30. Rodriguez R.A., Hae R., Spence M., et al. A Systematic Review and Metaanalysis of Nonpharmacologic-based Interventions for Aortic Stiffness in End-Stage Renal Disease. Kidney Internat. Rep. 2019;4(8):1109-21. https://doi. org/10.1016/j.ekir.2019.05.011

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies